Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (08) : 792-798     DOI: 10.3971/j.issn.1000-8578.2022.22.0039
|
Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum
JIA Lijuan1,2, ZHANG Yunqiang3, ZHANG Baihong2, YUE Hongyun4
1. The First Clinical Medicine College of Gansu University of Chinese Medicine, Lanzhou 730000, China; 2. Department of Oncology, The 940th Hospital of Joint Logistics Support Force of People’s Liberation Army, Lanzhou 730050, China; 3. Second Department of General Surgery, Gansu Provincial People’s Hospital, Lanzhou 730000, China; 4. Department of Ophthalmology, The 940th Hospital of Joint Logistics Support Force of People’s Liberation Army, Lanzhou 730050, China
Download: PDF(6197 KB)   ( 35 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the expression of m6A methylatransferase ZC3H13 in tissues and peripheral blood of patients with gastric cancer and its application value in gastric cancer. Methods UALCAN and GEPIA databases were used to analyze the expression difference of ZC3H13 in gastric cancer and adjacent normal tissues at transcription level; GEPIA and Kaplan-Meier Plotter databases were used to analyze the correlation between ZC3H13 expression level and OS of gastric cancer patients. ELISA was used to determine the concentration of ZC3H13 in 80 newly-diagnosed gastric cancer patients and 50 healthy controls, and to analyze its relation with clinicopathological data; IHC method was used to detect the expression level of ZC3H13 in 74 cases of cancer tissues and 40 cases of unpaired paracancerous tissues, and to analyze its relation with clinicopathological data. Results The expression of ZC3H13 in gastric cancer tissues was significantly higher than that in adjacent gastric tissues (P<0.05). The positive rate of ZC3H13 protein in gastric cancer tissues was significantly higher than that in adjacent normal tissues (74.3% vs. 52.5%, P<0.05). Serum ZC3H13 concentration in gastric cancer group was significantly higher than that in healthy control group (P<0.05). The expression level of ZC3H13 in gastric cancer tissues and peripheral blood was related to gender, differentiation degree, clinical stage and infiltration depth of gastric cancer (P<0.05). Multivariate analysis showed that ZC3H13 expression was not an independent risk factor for poor prognosis of gastric cancer patients (P>0.05). The AUC was 0.826 (P<0.05), indicating good diagnostic value. The critical value of serum ZC3H13 protein concentration was 4.87 ng/ml, and the sensitivity and specificity of ZC3H13 in the diagnosis of gastric cancer were 98.8% and 50.0%. Conclusion ZC3H13 is highly-expressed in gastric cancer tissues, and the concentration of ZC3H13 protein in peripheral blood is also significantly increased. ZC3H13 may play an important role in the occurrence and development of gastric cancer, and has certain clinical diagnostic value for gastric cancer.
Keywords Gastric cancer      ZC3H13      Prognosis     
ZTFLH:  R735.2  
Fund:Natural Science Foundation of Gansu Province (No. 1308RJZA181); Gansu Province Education Science and Technology Innovation Project Outstanding Graduate Innovation Star Project (No. 2021CXZX-739)
Issue Date: 11 August 2022
 Cite this article:   
JIA Lijuan,ZHANG Yunqiang,ZHANG Baihong, et al. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0039
http://www.zlfzyj.com/EN/Y2022/V49/I08/792
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
JIA Lijuan
ZHANG Yunqiang
ZHANG Baihong
YUE Hongyun
[1] Siegel RL, Miller KD, Fuchs Hannah E, et al. Cancer statistics,
2022[J]. CA Cancer J Clin, 2022, 72 (1): 7-33.
[2] Knuckles P, Lence T, Haussmann IU, et al. Zc3h13/Flacc is
required for adenosine methylation by brid-ging the mRNAbinding
factor Rbm15/Spenito to the m6A machinery component
Wtap/Fl(2)d[J]. Genes Dev, 2018, 32(5-6): 415-429.
[3] Chen M, Nie ZY, Wen XH, et al. m6A RNA methylation regulators
can contribute to malignant progression and impact the prognosis
of bladder cancer[J]. Biosci Rep, 2019, 39(12): BSR20192892.
[4] Chen J, Yu K, Zhong G, et al. Identification of a m6A RNA
methylation regulators-based signature for predicting the
prognosis of clear cell renal carcinoma[J]. Cancer Cell Int, 2020,

20: 157.

[5] Hou J, Shan H, Zhang Y, et al. m6A RNA methylation regulators
have prognostic value in papillary thyroid carcinoma[J]. Am J
Otolaryngol, 2020, 41(4): 102547.
[6] Zhai J, Li S, Sen S, et al. m6A RNA Methylation Regulators
Contribute to Eutopic Endometrium and Myometrium
Dysfunction in Adenomyosis[J]. Front Genet, 2020, 11: 716.
[7] Zhuang Z, Chen L, Mao Y, et al. Diagnostic, progressive and
prognostic performance of m6A methylation RNA regulators in
lung adenocarcinoma[J]. Int J Biol Sci, 2020, 16(11): 1785-1797.
[8] Pan J, Xu L, Pan H. Development and Validation of an m6A RNA
Methylation Regulator-Based Signature for Prognostic Prediction
in Cervical Squamous Cell Carcinoma[J]. Front Oncol, 2020, 10:
1444.
[9] Trilla-Fuertes L, Ghanem I, Maurel J, et al. Comprehensive
Characterization of the Mutational Landscape in Localized Anal
Squamous Cell Carcinoma[J]. Transl Oncol, 2020, 13(7): 100778.
[10] Fan L, Lin Y, Lei H, et al. A newly defined risk signature,
consisting of three m6A RNA methylation regulators, predicts the
prognosis of ovarian cancer[J]. Aging (Albany NY), 2020, 12(18):
18453-18475.
[11] Chandrashekard DS, Bashele B, Balasubramanys SAH, et al.
UALCAN: a portal for facilitating tumor subgroup gene
expr‍ession and survival analyses[J]. Neoplasia, 2017, 19(8):
649-658.
[12] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and
normal gene expr‍ession profiling and interactive analyses[J].
Nucleic Acids Res, 2017, 45(W1): W98-W102.
[13] Nagy á, Lánczky A, Menyhárt O, et al. Validation of miRNA
prognostic power in hepatocellular carcinoma using expr‍ession
data of independent datasets[J]. Sci Rep, 2018, 8(1): 9227.
[14] Allemani C, Matsuda T, Carlo DV, et al. Global surveillance of
trends in cancer survival 2000-14 (CONCORD-3): analysis of
individual records for 37 513 025 patients diagnosed with one of
18 cancers from 322 population-based registries in 71 countries[J].
Lancet, 2018, 391(10125): 1023-1075.
[15] Ouna BA, Stewart M, Helbig C, et al. The Trypanosoma brucei
CCCH zinc finger proteins ZC3H12 and ZC3H13[J]. Mol
Biochem Parasitol, 2012, 183(2): 184-188.
[16] Wen J, Lv R, Ma H, et al. ZC3H13 Regulates Nuclear RNA m6A
Methylation and Mouse Embryonic Stem Cell Self-Renewal[J].
Mol Cell, 2018, 69(6): 1028-1038.e6.
[17] Huang HL, Weng HY, Chen JJ. m6A Modification in Coding
and Non-coding RNAs: Roles and Therapeutic Implications in
Cancer[J]. Cancer Cell, 2020, 37(3): 270-288.
[18] Wei WQ, Ji XY, Guo XQ, et al. Regulatory role of N6-
methyladenosine (m6A) methylation in RNA processing and
human diseases[J]. J Cell Biochem, 2017, 118(9): 2534-2543.
[19] Zhu D, Zhou J, Zhao J, et al. ZC3H13 suppresses colorectal cancer
proliferation and invasion via inactivating Ras-ERK signaling[J].
J Cell Physiol, 2019, 234(6): 8899-8907.
[20] Gong PJ, Shao YC, Yang Y, et al. Analysis of N6-Methyladenosine
Methyltransferase Reveals METTL14 and ZC3H13 as Tumor
Suppressor Genes in Breast Cancer[J]. Front Oncol, 2020, 10:
578963.
[21] Guo T, Duan H, Chen J, et al. N6-Methyladenosine Writer
Gene ZC3H13 Predicts Immune Phenotype and Therapeutic
Opportunities in Kidney Renal Clear Cell Carcinoma[J]. Front
Oncol, 2021, 11: 718644.

Related articles from Frontiers Journals
[1] WANG Yue, ZHAO Weizhe, LI Xiaojie, NAN Mengdie, XIE Meiwen, LI Peijin, HOU Li. Traditional Chinese Medicine Combined with Chemotherapy in Prevention and Treatment of Recurrence and Metastasis of Locally Advanced Gastric Cancer After Radical Resection: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 913-922.
[2] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[3] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[4] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[5] TANG Wenhao. Negative Feedback Mechanism of Entero-gastric Inhibitory in Delayed Gastric Emptying Following Surgery for Stomach Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 760-763.
[6] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[7] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[8] WANG Daorong, WANG Wei. History and Current Situation of Digestive Tract Reconstruction After Laparoscopic Proximal Radical Gastrectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 644-648.
[9] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[10] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[11] ZHANG Rui, PENG Tao, YIN Jian, SONG Song, WANG Shen, MI Zihan, CHEN Wen, REN Jiansong. Expression and Significance of Serum DKK1 in Gastric Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 692-697.
[12] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[13] LU Shunli, YU Jianping, CHEN Weikai, LI Andong, HE Qingyuan, CHEN Chao, HAN Xiaopeng. Research Progress of Genes Related to Treatment and Prognosis of Alpha-fetoprotein Producing Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 738-744.
[14] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[15] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed